Can Polyphenols Redefine Eye Care?
A rosmarinic acid–based nanoplatform targets oxidative stress, inflammation and ocular-surface damage
Dry-eye disease is more than insufficient tear production. It involves a self-perpetuating cycle of oxidative stress, inflammation and epithelial injury, while conventional eye drops are often limited by rapid clearance from the ocular surface.
A recent study by Zixin Wang, Zeen Lv, Yuxuan Ge, Ruiyang Xue, Fang Wu, Haijie Han, Yin Wang and colleagues, published in Nature Communications, introduces a new approach based on a polyphenol-derived therapeutic platform.
The researchers used rosmarinic acid, a natural polyphenol, as both a bioactive compound and a structural component. Through self-polymerization in the presence of hyaluronic acid, followed by assembly with cerium ions, they produced multifunctional nanoparticles designed for use as eye drops. Thiol groups were then added to improve adhesion to the mucus-covered ocular surface and prolong local retention.
This design addresses several mechanisms simultaneously:
- Scavenging reactive oxygen species;
- Suppressing ocular inflammation;
- Supporting corneal epithelial repair;
- Improving tear secretion;
- Extending contact with the eye surface.
In two mouse models of dry-eye disease, topical administration reduced inflammation, repaired corneal epithelial defects and restored tear production. The results remain preclinical, but they demonstrate how a natural polyphenol can be transformed into an engineered therapeutic material rather than used only as a conventional antioxidant ingredient.
The study raises a broader question for polyphenol science:
Can polyphenols become the building blocks of next-generation precision therapies?
This new direction-from natural bioactive molecules to functional biomaterials and targeted delivery systems—will be highlighted at Polyphenols Applications 2026, taking place on October 8–9, 2026, in Málaga, Spain.
For more information:
Read the full news here
